Preclinical characterization of BCX17725, a potent inhibitor of KLK5/14, for the treatment of Netherton Syndrome

BCX17725 - BioCryst Pharmaceuticals

https://eppro02.ativ.me/web/page.php?page=IntHtml&project=SID2026&id=4507859

Yuanyuan Ma 1; Xiaogang Cheng 1; Qingde Liu 1; Stephen Nestor 1; Cynthia Parker 1; Juan Wang* 1; Mousheng Wu 1; Fugang Zhu 1; Y.S. Babu 1; Xilin Chen 1

May 18, 2026